Skip to content

Trial Summary

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.



ACTRN/NCT /ethics:


Scientific title:

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Sponsor / Cooperative group:

Navire Pharma Inc., a BridgeBio company

Trial & Patient Characteristics

Cancer TypeSolid cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Advanced
Anticipated Start Date2020-11-12
Anticipated End Date2023-10-01

Participating Hospitals

HospitalCancer Research SA
Clinical Trial CoordinatorKelly Mead/Kate Penda
Phone08 8359 2565
Principal InvestigatorDr Rohit Joshi/Dr Vineet Kwatra
Recruitment StatusRecruiting